AMJ Global Technology reported third-quarter 2025 results marked by nascent revenue and a wider net loss as the company recorded an impairment charge. Revenue for the quarter was $232 up from $8 in the year-ago quarter, while net loss widened to $934274 and diluted loss per share was $(0.01).
Financial Highlights
- Revenue: $232 for 3Q 2025, up from $8 in 3Q 2024 (+$224 YoY), driven by related-party Medicare revenue sharing.
- Net income: Net loss $934,274 for 3Q 2025, compared with net loss $50,825 in 3Q 2024; the wider loss was driven by an $886,232 impairment.
- Diluted EPS: $(0.01) for 3Q 2025 vs $(0.00) for 3Q 2024.
Business Highlights
- Revenue momentum: The company recognized minimal related-party revenue from Medicare revenue-sharing, increasing from $8 to $232 for the quarter, indicating early-stage commercial receipts.
- Strategic shift: AMJ moved its operational focus from mobile software to holistic tech-based health treatments and sports health, targeting PTSD and neurodegenerative care.
- Partnerships and IP actions: The company executed and later unwound several software and asset arrangements, including cancellation of an ElephantSqlDB® equity issuance and multiple unwind agreements.
- Service channel development: Management is pursuing Medicare, life and annuity channels through revenue-sharing agreements with related parties to develop recurring referral revenue streams.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.